Radiation Oncology CME Courses
Radiation Oncology CME Courses
Explore Key Topics
Featuring experts in the practice of Radiation Oncology, this CME program focuses on core concepts and emerging trends. Radiation Oncology – A Comprehensive Review includes case-based lectures on topics like proton radiation therapy in adults, radiation therapy for prostate cancer, spine stereotactic body radiation therapy, soft tissue sarcomas, skin cancer, and more. It will help you to better:
- Recognize the importance of clinical evaluation of cancer patients during various treatment phases
- Outline effective curative and palliative treatment goals
- Explain the potential outcomes of combining immunotherapy and radiation therapy
- Discuss the efficacy of stereotactic body radiation for spinal tumors
- Evaluate and overcome challenges encountered in radiation oncology
By the end of the session the participant will be able to:
- Apply screening criteria to a patient receiving AI therapy or androgen deprivation therapy
- Describe the criteria for initiation of pharmacotherapy in a patient receiving AI therapy or androgen deprivation therapy and apply them to a patient case
- Identify present pharmacotherapeutic treatments for management of a patient receiving AI therapy or androgen deprivation therapy, and describe their mechanisms of action and place in therapy
- Describe the challenges associated with treating patients receiving AI or androgen deprivation therapies, focus specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents and apply the information in optimizing patient care in a patient case
This inclusive review is designed to offer trainees and or clinicians in practice an update of clinical information as well as to help them prepare for their Radiation Oncology exams (initial certifications and MOC). The 4-day program includes didactic lectures with review questions, esyllabus (containing all PowerPoint® presentations), and designated Q&A sessions. Emphasis is on evidence-based medicine and board-relevant standards of care; incorporating new ideas, treatments, and imaging approaches. In addition, the course will cover the fundamentals of radiobiology and physics that are relevant to clinical practice. The written exams emphasize anatomy, epidemiology, etiological agents, natural history, pathology, tumor markers, the initial clinical evaluation, staging, routes of spread, selection of treatment modality and techniques, surgical and chemotherapy adjuvant treatments, follow-up treatment and evaluation, patterns of failure, and normal tissue effects including difficulties, all of these areas will be discussed in this course.
Topics covered: Pediatric Radiation Oncology *** Esophageal Cancer *** Gastric Cancer *** Pancreatic Cancer *** Colorectal Cancer *** Anal Cancer *** Hepatic and Cholangio Cancer *** Malignant Brain Tumors *** Benign Brain Tumors *** Metastases and Palliation *** Skin Tumors *** Hodgkin's Lymphoma and Plasmacytoma *** Non-Hodgkin's Lymphoma *** Head and Neck Anatomy *** General Principles *** Oropharyngeal *** Carcinoma in-situ and Miscellaneous*** Testis, Kidney, Ureter and Penis Cancer *** Early Stage Prostate Cancer *** Advanced Stage Prostate cancer *** Endometrial Cancer *** Sarcomas *** Vulvar and Vaginal Cancer *** Ovarian, Cervix and Fallopian Tubes Cancer *** Early Stage Breast Cancer *** Locally Advanced Breast Cancer ***Bladder Cancer *** Oral Cavity *** Larynx, Hypopharynx *** Nasopharynx *** Lung/Mediastinum *** Questions and Answers
By the end of the session the participant will be able to:
- Apply existing guideline recommendations in the diagnosis of HCC
- Identify present and emerging pharmacotherapeutic treatments for management of unresectable HCC and apply them to patient cases using evidence-based medicine.
- Describe how to manage challenges that arise during treatment with present and emerging pharmacotherapeutic treatments for HCC, including adverse effect management, and apply that knowledge to a patient case
- Describe the challenges associated with treating patients with HCC, focusing specifically on the risks (e.g., adverse drug reactions, drug interactions, et cetera) of the agents used to treat the disease, and apply that information in optimizing patient care in a patient case